NOTE TO AFFILIATES:
Please verify tablet images for accuracy and Reference based on local labelling
Week 0-8: Induction
Week 8-16: For patients who do not achieve adequate therapeutic benefit by Week 8, may be continued for an additional 8 weeks
After Week 16: Discontinue in any patient who shows no evidence of therapeutic benefit by Week 16
The recommended maintenance dose of RINVOQ is 15 mg or 30 mg once daily based on individual patient presentation.
A dose of 30 mg once daily may be appropriate for some patients, such as:
Patients with high disease burden or requiring 16-week induction treatment
Patients who do not show adequate therapeutic benefit to 15 mg once daily
For patients ≥65 years of age, the recommended dose is 15 mg once daily.
The lowest effective dose for maintenance should be considered.
RINVOQ is to be taken orally once daily with or without food & may be taken at any time of the day. Tablets should be swallowed whole and should not be split, crushed, or chewed.1
Full information about RINVOQ’s dosing information in UC can be found in the SmPC.
*estimated glomerular filtration rate 15 to <30 ml/min/1.73m2.
- Hypersensitivity to the active substance or to any of its excipients
- Active tuberculosis or active serious infections
- Severe hepatic impairment
- Pregnancy
The safety and efficacy of RINVOQ in children and adolescents with ulcerative colitis aged 0 to less than 18 years have not yet been established. No data are available.
The safety and efficacy of RINVOQ in patients aged 75 and older have not yet been established.
The use of RINVOQ has not been studied in subjects with end-stage renal disease and is not recommended for use in these patients.
RINVOQ should not be used during breast-feeding.
Please consult the Summary of Product Characteristics for further details regarding contraindications, monitoring requirements and additional prescribing information prior to initiating RINVOQ
CYP3A4: cytochrome P3A4; UC: ulcerative colitis.
Watch this Introduction to RINVOQ video, for patients prescribed RINVOQ. This video is supplementary to the Patient Information Leaflet.
[Note to Affiliate: HCP-delivered patient materials and their inclusion herein are subject to local codes and regulations.]
Meet three moderately to severely active UC patients* (Andrew, Meera and Issac), and learn more about how RINVOQ treatment could be helpful to them.
*Hypothetical patient cases.
They could be suitable for treatment with RINVOQ
[Affiliates to insert content once available, subject to approval and as applicable per local regulations]
Not actual patients; for illustrative purposes only.
Consider the risks and benefits of treatment prior to initiating RINVOQ.1
Note for affiliates: If these patient profiles are used, the following reference should be added and renumbered in sequential order within an affiliate's CLM: Reference: 1. RINVOQ Summary of Product Characteristics.
REFERENCES
- RINVOQ Summary of Product Characteristics.
- Danese S, Vermeire S, Zhou W, et al. Lancet. 2022;399(10341):2113–2128.